Recursion Pharmaceuticals, Inc. RXRX Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current?
- Recursion Pharmaceuticals, Inc. (RXRX) reported contract liabilities, non-current of $114.72M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current decreased by 11.5% year-over-year, from $129.61M to $114.72M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s contract liabilities, non-current has grown at a 46.9% compound annual growth rate (CAGR), from $16.67M to $114.01M.